MedTrace Logo

Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study

NCT05284097 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2025-05-11

No results posted yet for this study

Summary

This is a Phase 2, open-label, study evaluating the safety and immunogenicity of the 2-dose vaccination regimen, Ad26.ZEBOV, MVA-BN-Filo, in adults and children originally enrolled in the control arm of the EBOVAC-Salone study

Conditions

  • Virus Diseases
  • Hemorrhagic Fever, Ebola
  • Infections
  • Hemorrhagic Fevers, Viral
  • RNA Virus Infections
  • Filoviridae Infections
  • Mononegavirales Infections
  • Vaccines
  • Immunologic Factors
  • Physiological Effects of Drugs
  • Ebola

Interventions

DRUG

Ad26.ZEBOV, MVA-BN-Filo

Ad26.ZEBOV - is an adenovirus serotype 26 vector expressing the glycoprotein (GP) of the Ebola virus (EBOV) Mayinga variant MVA-BN-Filo - is a Modified Vaccinia Ankara (MVA) - Bavarian Nordic (BN) vector expressing the GPs of EBOV, Sudan virus (SUDV) and Marburg virus (MARV) and the nucleoprotein of Tai Forest virus

Sponsors & Collaborators

  • University of Sierra Leone

    collaborator OTHER

  • Janssen Vaccines & Prevention B.V.

    collaborator INDUSTRY

  • London School of Hygiene and Tropical Medicine

    lead OTHER

Principal Investigators

  • Deborah Watson-Jones, PhD · London School of Hygiene and Tropical Medicine

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-19
Primary Completion
2023-03-02
Completion
2024-10-31

Countries

  • Sierra Leone

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05284097 on ClinicalTrials.gov